Market capitalization | $953.96m |
Enterprise Value | $1.80b |
P/E (TTM) P/E ratio | 12.76 |
EV/FCF (TTM) EV/FCF | 9.37 |
EV/Sales (TTM) EV/Sales | 3.01 |
P/S ratio (TTM) P/S ratio | 1.59 |
P/B ratio (TTM) P/B ratio | 4.07 |
Revenue growth (TTM) Revenue growth | 9.62% |
Revenue (TTM) Revenue | $599.25m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
5 Analysts have issued a Collegium Pharmaceutical, Inc. forecast:
5 Analysts have issued a Collegium Pharmaceutical, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 599 599 |
10%
10%
|
|
Gross Profit | 374 374 |
31%
31%
|
|
EBITDA | 361 361 |
28%
28%
|
EBIT (Operating Income) EBIT | 213 213 |
64%
64%
|
Net Profit | 89 89 |
882%
882%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.
Head office | United States |
CEO | Vikram Karnani |
Employees | 197 |
Founded | 2002 |
Website | www.collegiumpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.